Feasibility and efficacy of robotic complete mesocolic excision (CME) with intracorporeal anastomosis for right colon cancer were analyzed in 110 patients. Results show a median operative time of 184 minutes, minimal blood loss, and low complication rates. Conversions were minimal, with acceptable postoperative outcomes. Robotic CME with central vessels ligation appears safe and effective for treating right colon cancer.
A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.
Five years after surgery for low rectal cancer, patients operated on robotically did as well as those operated on laparoscopically, according to a randomized trial from three Korean centres.
